The headline reads as positive (91% confidence from the FinBERT financial-language model), so the stock went through the full analysis. The broader analysis agrees with the good news.
Stocks › LEGN
Legend Biotech Corporation (LEGN) stock analysis
WEAK BUY 23% confidence · analysed Oct 15, 2026
On Oct 15, 2026, our model rated Legend Biotech Corporation (LEGN) WEAK BUY with 23% confidence at a price of $19.04. That means the signals lean positive, but they are mixed, so conviction is low.
SectorHealthcare
IndustryBiotechnology
Market cap3.70B
Analysed price$19.04
Technical picture
The 14-day RSI is 50, close to the neutral 50 line, so momentum is balanced.
MACD is above its signal line, a sign that short-term momentum is turning up.
The price is below both its 50-day and 200-day moving averages, the classic picture of a downtrend.
Volume is 1.6x its 20-day average, so the latest move has real participation behind it.
Trend structure and money flow
Market structure: ranging / no clear structure.
The most recent swing high is $37.50 and the swing low is $16.24; traders often treat these as resistance and support.
Fundamentals
The company reports a profit margin of -7.2% and revenue growth of +51.9%.
In its latest quarter it earned $0.32 per share, which beat the $0.28 analysts expected, with revenue +51.9% year over year.
Wall Street's average rating is 2.2 on a 1 (strong buy) to 5 (sell) scale, roughly a "buy", with an average price target of $45.62.
The next earnings report is expected around Nov 11, 2026; prices often move sharply around earnings.
Trade plan from the model
The model's long / bullish plan uses an entry near $19.73, a target of $21.31 (+8.0%) and a stop-loss at $17.87 (-9.4%).
That is a reward-to-risk ratio of about 0.8 to 1: the potential loss is bigger than the gain, a weak setup.
The plan has a time limit: reassess by Oct 25, 2026 whatever the price does.
Entry$19.73
Target$21.31
Stop-loss$17.87
Reassess byOct 25, 2026
The model's one-paragraph read
Leans BUY — composite score +0.23 (WEAK BUY). Technicals: RSI 49.84, MACD bullish, price below SMA50. Fundamentals: margin -7.2%, revenue growth 51.9%. Financial results: YoY revenue +51.9%, last EPS surprise +14.3%, next earnings 2026-11-11. Smart Money Concepts: ranging / no clear structure. FinGPT news read: neutral. Memory: 1 prior look(s). Suggested levels: entry $19.73, target $21.31, stop-loss $17.87, exit by 2026-10-25 (10-calendar-day max hold (time-stop; reassess by this date regardless of P&L)).
Past ratings for LEGN
| Date | Verdict | Confidence | Price | Move since | |
|---|---|---|---|---|---|
| Oct 15, 2026 | WEAK BUY | 23% | $19.04 | — |
"Move since" compares each call's price with the latest analysed price.
Recent news on LEGN
Oct 15, 2026 · Legend Biotech Announces U.S. FDA Clearance of IND Application for LB2501, an Investigational CD19/CD20 In Vivo CAR-T Therapy
- Oct 15, 2026: Legend Biotech Announces U.S. FDA Clearance of IND Application for LB2501, an Investigational CD19/CD20 In Vivo CAR-T Therapy (GlobeNewswire)
Other Healthcare stocks we cover
LH · LLY · LQDA · MDT · NRC · NVO · OSCR · PCRX · PFE · PGNY · PHG · PHR
Frequently asked questions
Is LEGN a buy right now?
As of Oct 15, 2026, our automated model rates Legend Biotech Corporation (LEGN) WEAK BUY with 23% confidence: the signals lean positive, but they are mixed, so conviction is low. This is a model output for education, not personal investment advice.
What is the price target for LEGN?
The model's most recent plan targets $21.31 with a stop-loss at $17.87, from an entry near $19.73.
When does Legend Biotech Corporation report earnings next?
The next earnings report is expected around Nov 11, 2026.
What does a WEAK BUY rating mean?
A WEAK BUY rating means the signals lean positive, but they are mixed, so conviction is low.
For information and education only. Not investment advice. Ratings are produced by an automated model, can be wrong, and may be out of date. Do your own research; you can lose money investing. The site's author may hold positions in stocks discussed here.